D-serine in neurobiology: CNS neurotransmission and neuromodulation

Canadian Journal of Neurological Sciences

Volumn 41, Issue 2, 2014, Pages 164-176

  Bardaweel, Sanaa K ^a   Alzweiri, Muhammed ^a   Ishaqat, Aman A ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRO SERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; GLUTAMIC ACID; SERINE;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; AMYOTROPHIC LATERAL SCLEROSIS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DISEASE ASSOCIATION; EPILEPSY; EXCITOTOXICITY; HUMAN; LEARNING; MEMORY; MENTAL DISEASE; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PERINATAL ASPHYXIA; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; ANIMAL; EMBRYOLOGY; GROWTH, DEVELOPMENT AND AGING; HYPOXIC ISCHEMIC ENCEPHALOPATHY; METABOLISM; NERVE CELL PLASTICITY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CENTRAL NERVOUS SYSTEM; EPILEPSY; GLUTAMIC ACID; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; NEURONAL PLASTICITY; NEUROTRANSMITTER AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SERINE; SYNAPTIC TRANSMISSION;

EID: 84894473010     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710001653X     Document Type: Review

References (213)

1. Lamzin VS, Dauter Z, Wilson KS. How nature deals with stereoisomers. Curr opin Struct biol. 1995;5:830-6.
2. Mason Sf. Origins of biomolecular handedness. Nature. 1984;311: 19-23.
3. Prelog V. Chirality in chemistry. Science. 1976;193:17-24.
4. Auclair JL, Patton rl. On the occurrence of d-alanine in the haemolymph of the milkweed bug, Oncopeltus fasciatus. Rev Can biol. 1950;1:3-8.
5. Beatty I, Magrath D, Ennor A. Occurrence of d-serine in lombricine. Nature. 1959;183:591.
6. Corrigan JJ, Srinivasan ng. The occurrence of certain d-amino acids in insects. Biochemistry. 1966;5:1185-90.
7. Kreil G. Peptides containing a d-amino acid from frogs and molluscs. J biol Chem. 1994;269:10967-70.
8. Preston rl. Occurrence of d-amino acids in higher organisms: a survey of the distribution of d-amino acids in marine vertebrates. Comp biochem physiol B. 1987;87:55-62.
9. Dunlop DS, Neidle A, Mchale D, Dunlop DM, Lajtha A. The presence of free d-aspartic acid in rodents and man. Biochem biophys res Commun. 1986;141:27-32.
10. Hashimoto A, Nishikawa T, Hayashi T, et al. The presence of free d-serine in rat brain. FebS lett. 1992;269:33-6.
11. Hashimoto A, Kumashiro S, Nishikawa T, et al. Embryonic development and postnatal changes in free d-aspartate and dserine in the human prefrontal cortex. J neurochem. 1993;61: 348-51.
12. Gustafson EC, Stevens ER, Wolosker H, Miller rf. Endogenous dserine contributes to nMda receptor-mediated light-evoked responses in the vertebrate retina. J neurophysiol. 2007;98: 122-30.
13. Junjaud G, Rouaud E, Turpin F, Mothet JP, Billard JM. Age-related effects of the neuromodulator d-serine on neurotransmission and synaptic potentiation in the Ca1 hippocampal area of the rat. J neurochem. 2006;98:1159-66.
14. Mothet JP, Parent AT, Wolosker H, et al. D-Serine is an endogenous ligand for the glycine site of the n-methyl-d-aspartate receptor. Proc natl acad Sci uSa. 2000;97:4926-31.
15. Stevens ER, Esguerra M, Kim PM, et al. D-Serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of nMda receptors. Proc natl acad Sci uSa. 2003;100:6789-94.
16. Panatier A, Theodosis DT, Mothet JP, et al. Glia derived d-serine controls nMda receptor activity and synaptic memory. Cell. 2006;125:775-84.
17. Yang Y, Ge W, Chen Y, et al. Contribution of astrocytes to hippocampal long-term potentiation through release of d-serine. Proc natl acad Sci uSa. 2003;100:15194-9.
18. Yang S, Qiao H, Wen L, Zhou W, Zhang Y. D-Serine enhances impaired long-term potentiation in Ca1 subfield of hippocampal slices from aged senescence-accelerated mouse prone/8. Neurosci lett. 2005;379:7-12.
19. Kim PM, Aizawa H, Kim PS, et al. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc natl acad Sci uSa. 2005;102:2105-10.
20. Katsuki H, Nonaka M, Shirakawa H, Kume T, Akaike A. Endogenous d-serine is involved in induction of neuronal death by n-methyl-d-aspartate and simulated ischemia in rat cerebrocortical slices. J pharmacol exp ther. 2004;311:836-44.
21. Kartvelishvily E, Shleper M, Balan L, Dumin E, Wolosker H. Neuron-derived d-serine release provides a novel means to activate n-methyl-d-aspartate receptors. J biol Chem. 2006; 281:14151-62.
22. Katsuki H, Watanabe Y, Fujimoto S, Kume T, Akaike A. Contribution of endogenous glycine and d-serine to excitotoxic and ischemic cell death in rat cerebrocortical slice cultures. Life Sci. 2007;81:740-9.
23. Sasabe J, Chiba T, Yamada M, et al. D-Serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMbo J. 2007;26:4149-59.
24. Shleper M, Kartvelishvily E, Wolosker H. D-Serine is the dominant endogenous coagonist for nMda receptor neurotoxicity in organotypic hippocampal slices. J neurosci. 2005;25:9413-7.
25. Wu SZ, Bodles AM, Porter MM, Griffin WS, Basile AS, Barger SW. Induction of serine racemase expression and d-serine release from microglia by amyloid beta-peptide. J neuroinflamm. 2004;1:2-13
26. Schell MJ, Molliver ME, Snyder SH. D-Serine, An endogenous synaptic modulator: localization to astrocytes and glutamatestimulated release. Proc natl acad Sci uSa. 1995;92:3948-52.
27. Puyal J, Martineau M, Mothet JP, Nicolas MT, Raymond J. Changes in d-serine levels and localization during postnatal development of the rat vestibular nuclei. J Comp neurol. 2006; 497:610-21.
28. Van horn MR, Sild M, Ruthazer eS. D-Serine as a gliotransmitter and its roles in brain development and disease. Front Cell neurosci. 2013;7:39-52.
29. De Miranda J, Panizzutti R, Foltyn VN, Wolosker H. Cofactors of serine racemase that physiologically stimulate the synthesis of the n-methyl-d-aspartate (nMda) receptor coagonist d-serine. Proc natl acad Sci uSa. 2002;99:14542-7.
30. Wolosker H, Blackshaw S, Snyder Sh. Serine racemase: a glial enzyme synthesizing d-serine to regulate glutamate-n-methyld-aspartate neurotransmission. Proc natl acad Sci uSa. 1999; 96:13409-14.
31. Wolosker H, Sheth KN, Takahashi M, et al. Purification of serine racemase: biosynthesis of the neuromodulator d-serine. Proc natl acad Sci uSa. 1999;96:721-5.
32. Cook SP, Galve-roperh I, Martinezdelpozo A, Rodriguez-Crespo I. Direct calcium binding results in activation of brain serine racemase. J biol Chem. 2002;277:27782-92.
33. Neidle A, Dunlop dS. Allosteric regulation of mouse brain serine racemase. Neurochem res. 2002;27:1719-24.
34. Strisovsky K, Jiraskova J, Barinka C, et al. Mouse brain serine racemase catalyzes specific elimination of l-serine to pyruvate. FebS lett. 2003;535:44-8.
35. Wang LZ, Zhu XZ. Spatiotemporal relationships among d-serine, Serine racemase, and d-amino acid oxidase during mouse postnatal development. Acta pharmacol Sin. 2003;24:965-74.
36. De Miranda J, Santoro A, Engelender S, Wolosker H. Human serine racemase: molecular cloning, Genomic organization and functional analysis. Gene. 2000;256:183-8.
37. Basu AC, Tsai GE, Hani L, et al. Abnormal sensory gating, Reversal of spatial memory, and anxiety-like behavior in serine racemase knockout mice. Soc neurosci abstr. 2007;275:3514-26.
38. Ma CL, Tsai GE, Coyle JT, Basu AC, Bergeron R. Serine racemase null mutant mice show disrupted nMda receptor function at the hippocampal schaffer collateral-Ca1 pyramidal cell synapse. Soc neurosci abstr. 2007;576.
39. Mustafa AK, Ehmsen JT, Zeynalov E, et al. D-Serine deficient mice display nMda receptor dysfunction and reduced stroke damage. Soc neurosci abstr. 2007;576.
40. Zhao YL, Takata Y, Hashimoto K, Sakimura K, Mori H. Study of d-serine function in vivo by establishing and analysis of serine racemase knockout mouse. Neurosci res. 2007;58:346-52.
41. Benneyworth MA, Li Y, Basu AC, Bolshakov VY, Coyle Jt. Cell selective conditional null mutations of serine racemase demonstrate a predominate localization in cortical glutamatergic neurons. Cell Mol neurobiol. 2012;32:613-24.
42. Foltyn VN, Bendikov I, De Miranda J, et al. Serine racemase modulates intracellular d-serine levels through an alpha,betaelimination activity. J biol Chem. 2005;3:1754-63.
43. Furuya S, Tabata T, Mitoma J, et al. L-Serine and glycine serve as major astroglia-derived trophic factors for cerebellar purkinje neurons. Proc natl acad Sci uSa. 2000;97:11528-33.
44. Yamasaki M, Yamada K, Furuya S, Mitoma J, Hirabayashi Y, Watanabe M. 3-phosphoglycerate dehydrogenase, A key enzyme for l-serine biosynthesis, Is preferentially expressed in the radial glia/astrocyte lineage and olfactory ensheathing glia in the mouse brain. J neurosci. 2001;21:7691-704.
45. Wolosker H. Serine racemase and the serine shuttle between neurons and astrocytes. Biochim biophys acta. 2011;1814: 1558-66.
46. Krebs ha. Metabolism of amino acids. Iii. Determination of amino acids. Biochem J. 1935;29:1620-44.
47. Pollegioni L, Harris CM, Molla G, Pilone MS, Ghisla S. Identification and role of ionizing functional groups at the active center of rhodotorula gracilis d-amino acid oxidase. FebS lett. 2001;507:323-6.
48. Hashimoto A, Nishikawa T, Konno R, et al. Free d-serine, Daspartate and d-alanine in central nervous system and serum in mutant mice lacking d-amino acid oxidase. Neurosci lett. 1993; 152:33-6.
49. Morikawa A, Hamase K, Inoue T, Konno R, Niwa A, Zaitsu K. Determination of free d-aspartic acid, D-serine and d-alanine in the brain of mutant mice lacking d-amino acid oxidase activity. J Chromatogr b biomed Sci appl. 2001;757:119-25.
50. D'aniello A, Vetere A, Petrucelli L. Further study on the specificity of d-amino acid oxidase and d-aspartate oxidase and time course for complete oxidation of d-amino acids. Comp biochem physiol B. 1993;105:731-4.
51. Nagata Y, Konno R, Yasumura Y, Akino T. Involvement of d-amino acid oxidase in elimination of free d-amino acids in mice. Biochem J. 1989;257:291-2.
52. Urai Y, Jinnouchi O, Kwak KT, Suzue A, Nagahiro S, Fukui K. Gene expression of d-amino acid oxidase in cultured rat astrocytes: regional and cell type specific expression. Neurosci lett. 2002;324:101-4.
53. Danysz W, Parsons Cg. Glycine and n-methyl-d-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol rev. 1998;4:597-664.
54. Paoletti P, Neyton J. NMda receptor subunits: function and pharmacology. Curr opin pharmacol. 2007;7:39-47.
55. Mcbain CJ, Kleckner NW, Wyrick S, Dingledine R. Structural requirements for activation of the glycine coagonist site of nmethyl-d-aspartate receptors expressed in Xenopus oocytes. Mol pharmacol. 1989;36:556-65.
56. Fadda E, Danysz W, Wroblewski JT, Costa E. Glycine and d-serine increase the affinity of n-methyl-d-aspartate sensitive glutamate binding sites in rat brain synaptic membranes. Neuropharmacology. 1988;27:1183-5.
57. Lerma J, Zukin RS, Bennett Mv. Glycine decreases desensitization of n-methyl-d-aspartate (nMda) receptors expressed in Xenopus oocytes and is required for nMda responses. Proc natl acad Sci uSa. 1990;87:2354-8.
58. Nong Y, Huang YQ, Ju W, et al. Glycine binding primes nMda receptor internalization. Nature. 2003;422:302-7.
59. Furukawa H, Gouaux E. Mechanisms of activation, Inhibition and specificity: crystal structures of the nMda receptor nr1 ligand-binding core. EMbo J. 2003;22:2873-85.
60. Constantine-paton M, Cline HT, Debski E. Patterned activity, Synaptic convergence, and the nMda receptor in developing visual pathways. Annu rev neurosci. 1990;13:129-54.
61. Henneberger C, Papouin T, Oliet SH, Rusakov da. Long-term potentiation depends on release of d-serine from astrocytes. Nature. 2010;463:232-6.
62. Stevens ER, Gustafson EC, Sullivan SJ, Esguerra M, Miller rf. Light-evoked nMda receptor-mediated currents are reduced by blocking d-serine synthesis in the salamander retina. Neuroreport. 2010;21:239-44.
63. Fossat P, Turpin FR, Sacchi S, et al. Glial d-serine gates nMda receptors at excitatory synapses in prefrontal cortex. Cereb Cortex. 2012;22:595-606.
64. Kaufman AM, Milnerwood AJ, Sepers MD, et al. Opposing roles of synaptic and extrasynaptic nMda receptor signaling in cocultured striatal and cortical neurons. J neurosci. 2012;32: 3992-4003.
65. Papouin T, Ladhe L, Ruel J, et al. Synaptic and extrasynaptic nMda receptors are gated by different endogenous coagonists. Cell. 2012;150:633-46.
66. Mothet JP, Rouaud E, Sinet PM, et al. A critical role for the glialderived neuromodulator d-serine in the age-related deficits of cellular mechanisms of learning and memory. Aging Cell. 2006; 5:267-74.
67. Berger AJ, Dieudonne S, Ascher P. Glycine uptake governs glycine site occupancy at nMda receptors of excitatory synapses. J neurophysiol. 1998;80:3336-40.
68. Bergeron R, Meyer TM, Coyle JT, Greene rW. Modulation of nmethyl-d-aspartate receptor function by glycine transport. Proc natl acad Sci uSa. 1998;95:15730-4.
69. Sakata Y, Owada Y, Sato K, et al. Structure and expression of the glycine cleavage system in rat central nervous system. Brain res Mol brain res. 2001;94:119-30.
70. Sato K, Yoshida S, Fujiwara K, Tada K, Tohyama M. Glycine cleavage system in astrocytes. Brain res. 1991;567:64-70.
71. Zafra F, Aragon C, Gimenez C. Molecular biology of glycinergic neurotransmission. Mol neurobiol. 1997;14:117-42.
72. Ribeiro CS, Reis M, Panizzutti R, De Miranda J, Wolosker H. Glial transport of the neuromodulator d-serine. Brain res. 2002;929: 202-9.
73. Fukasawa Y, Segawa H, Kim JY, et al. Identification and characterization of a na(+)-independent neutral amino acid transporter that associates with the 4f2 heavy chain and exhibits substrate selectivity for small neutral d-and l-amino acids. J biol Chem. 2000;275:9690-8.
74. Helboe L, Egebjerg J, Moller M, Thomsen C. Distribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. Eur J neurosci. 2003;18:2227-38.
75. Matsuo H, Kanai Y, Tokunaga M, et al. High affinity d-and lserine transporter asc-1: cloning and dendritic localization in the rat cerebral and cerebellar cortices. Neurosci lett. 2004;358: 123-6.
76. Nakauchi J, Matsuo H, Kim DK, et al. Cloning and characterization of a human brain na(+)-independent transporter for small neutral amino acids that transports d-serine with high affinity. Neurosci lett. 2000;287:231-5.
77. Hayashi F, Takahashi K, Nishikawa T. Uptake of d-and l-serine in C6 glioma cells. Neurosci lett. 1997;239:85-8.
78. Rutter AR, Fradley RL, Garrett EM, et al. Evidence from gene knockout studies implicates asc-1 as the primary transporter mediating d-serine reuptake in the mouse CnS. Eur J neurosci. 2007;25:1757-66.
79. Shao Z, Kamboj A, anderson CM. Functional and immunocytochemical characterization of d-serine transporters in cortical neuron and astrocyte cultures. J neurosci res. 2009;87:2520-30.
80. Horiike K, Tojo H, Arai R, Nozaki M, Maeda T. D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes. Brain res. 1994; 652:297-303.
81. Hashimoto A. Effect of the intracerebroventricular and systemic administration of l-serine on the concentrations of d-and lserine in several brain areas and periphery of rat. Brain res. 2002;955:214-20.
82. Boehning D, Snyder Sh. Novel neural modulators. Annu rev neurosci. 2003;26:105-31.
83. Hashimoto A, Oka T, Nishikawa T. Anatomical distribution and postnatal changes in endogenous free d-aspartate and d-serine in rat brain and periphery. Eur J neurosci. 1995;7:1657-63.
84. Chahal H, D'Souza SW, Barson AJ, Slater P. Modulation by magnesium of n-methyl-d-aspartate receptors in developing human brain. Arch dis Child fetal neonatal ed. 1998;78: f116-20.
85. Panigrahy A, Rosenberg PA, Assmann S, Foley EC, Kinney hC. Differential expression of glutamate receptor subtypes in human brainstem sites involved in perinatal hypoxia-ischemia. J Comp neurol. 2000;427:196-208.
86. Piggott MA, Perry EK, Perry RH, Court Ja. [3h]MK-801 binding to the nMda receptor complex, and its modulation in human frontal cortex during development and aging. Brain res. 1992; 588:277-86.
87. Slater P, McConnell SE, D'Souza SW, Barson aJ. Postnatal changes in n-methyl-d-aspartate receptor binding and stimulation by glutamate and glycine of [3h]-MK-801 binding in human temporal cortex. Br J pharmacol. 1993;108:1143-9.
88. Crair MC, Malenka rC. A critical period for long-term potentiation at thalamocortical synapses. Nature. 1995;375:325-8.
89. Feldman DE, Nicoll RA, Malenka RC, Isaac Jt. Long-term depression at thalamocortical synapses in developing rat somatosensory cortex. Neuron. 1998;21:347-57.
90. Ramoa AS, McCormick da. Enhanced activation of nMda receptor responses at the immature retinogeniculate synapse. J neurosci. 1994;14:2098-105.
91. Fuchs SA, Dorland L, De Sain-van der velden MG, et al. D-Serine in the developing human central nervous system. Ann neurol. 2006;60:476-80.
92. Komuro H, Rakic P. Modulation of neuronal migration by nMda receptors. Science. 1993;260:95-7.
93. Hepner F, Pollak A, Ulfig N, Yae-Kyung M, Lubec G. Mass spectrometrical analysis of human serine racemase in foetal brain. J neural transm. 2005;112:805-11.
94. Adesnik H, Li G, During MJ, Pleasure SJ, Nicoll ra. NMda receptors inhibit synapse unsilencing during brain development. Proc natl acad Sci uSa. 2008;105:5597-602.
95. Rabacchi S, Bailly Y, Delhaye-bouchaud N, Mariani J. Involvement of the n-methyl-d-aspartate (nMda) receptor in synapse elimination during cerebellar development. Science. 1992;256:1823-5.
96. Bliss TV, Collingridge gl. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31-9.
97. Basu AC, Tsai GE, Ma CL, et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol psychiatry. 2009;14:719-27.
98. Almond SL, Fradley RL, Armstrong EJ, et al. Behavioral and biochemical characterization of a mutant mouse strain lacking d-amino acid oxidase activity and its implications for schizophreni. Mol Cell neurosci. 2006;32:324-34.
99. Maekawa M, Watanabe M, Yamaguchi S, Konno R, Hori Y. Spatial learning and long-term potentiation of mutant mice lacking damino-acid oxidase. Neurosci res. 2005;53:34-8.
100. turpin FR, Potier B, Dulong JR, et al. Reduced serine racemase expression contributes to age-related deficits in hippocampal cognitive function. Neurobiol aging. 2009;8:1495-504.
101. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu rev neurosci. 1990;13: 171-82.
102. inoue R, Hashimoto K, Harai T, Mori H. NMda-and betaamyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J neurosci. 2008;28:14486-91.
103. paul P, De belleroche J. The role of d-amino acids in amyotrophic lateral sclerosis pathogenesis: a review. Amino acids. 2012;43: 1823-31.
104. bruijn LI, Miller TM, Cleveland dW. Unraveling the mechanisms involved in motor neurondegeneration in alS. Annu rev neurosci. 2004;27:723-49.
105. rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann neurol. 1990;28:18-25.
106. Mitchell J paul P, Chen HJ, et al. Familial amyotrophic lateral sclerosis is associated with a mutation in d-amino acid oxidase. Proc natl acad Sci uSa. 2010;107:7556-61.
107. olney JW, Wozniak DF, Farber nb. Excitotoxic neurodegeneration in alzheimer disease. New hypothesis and new therapeutic strategies. Arch neurol. 1997;54:1234-40.
108. Kornhuber J, Weller M. Psychotogenicity and n-methyl-daspartate receptor antagonism: implications for neurodegenerative pharmacotherapy. Biol psychiatry. 1997;41: 135-44.
109. newcomer JW, Krystal Jh. NMda receptor regulation of memory and behavior in humans. Hippocampus. 2001;11:529-42.
110. Loftis JM, Janowsky A. The n-methyl-d-aspartate receptor subunit nr2b: localization, Functional properties, Regulation, and clinical implications. Pharmacol ther. 2003;97:55-85.
111. Maragos WF, Chu DC, Young AB, D'amato CJ, Penney Jr Jb. Loss of hippocampal [3h]tCp binding in alzheimer's disease. Neurosci lett. 1987;74:371-6.
112. Procter AW, Wong EH, Stratmann GC, Lowe SL, Bowen dM. Reduced glycine stimulation of [3h]MK-801 binding in alzheimer's disease. J neurochem. 1989;53:698-704.
113. Sze C, Bi H, Kleinschmidt-deMasters BK, Filley CM, Martin lJ. N-Methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in alzheimer's disease. J neurol Sci. 2001;182:151-9.
114. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius hJ. Memantine Study group. Memantine in moderate-to-severe alzheimer's disease. N engl J Med. 2003;348:1333-41.
115. Suh YH, Checler F. Amyloid precursor protein, Presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in alzheimer's disease. Pharmacol rev. 2002;54: 469-525.
116. Brito-Moreira J, Paula-lima AC, Bomfim TR, et al. Abeta oligomers induce glutamate release from hippocampal neurons. Curr alzheimer res. 2011;5:552-62.
117. Wu S, Basile AS, Barger SW. Induction of serine racemase expression and d-serine release from microglia by secreted amyloid precursor protein (sapp). Curr alzheimer res. 2007;4: 243-51.
118. Peterson Sl. Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by d-serine and antagonized by 7-chlorokynurenic acid. Eur J pharmacol. 1991; 199:341-8.
119. Loscher W, Wlaz P, Rundfeldt C, Baran H, Honack D. Anticonvulsant effects of the glycine/nMda receptor ligands dcycloserine and d-serine but not r-(+)-ha-966 in amygdalakindled rats. Br J pharmacol. 1994;112:97-106.
120. Schwartz BL, Hashtroudi S, Herting RL, Schwartz P, Deutsch Si. D-Cycloserine enhances implicit memory in alzheimer patients. Neurology. 1996;46:420-4.
121. tsai G, Falk WE, Gunther J, Coyle Jt. Improved cognition in alzheimer's disease with short-term d-cycloserine treatment. Am J psychiatr. 1999;156:467-9.
122. andersen JM, Fonnum F, Myhrer T. D-Serine alleviates retrograde amnesia of a visual discrimination task in rats with a lesion of the perirhinal cortex. Brain res. 2003;979:240-4.
123. Singh L, Oles RJ, Tricklebank Md. Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the nMda receptor/ion channel complex. Br J pharmacol. 1990;99:285-8.
124. de SG, Trimarchi GR, Sinopoli S, Masuda Y, De Sa. Anticonvulsant effects of u-54494a and u-50488 h in genetically epilepsy-prone rats and dba/2 mice: a possible involvement of glycine/nMda receptor complex. Gen pharmacol. 1993;24:439-47.
125. peterson Sl. Infusion of nMda antagonists into the nucleus reticularis pontis oralis inhibits the maximal electroshock seizure response. Brain res. 1995;702:101-10.
126. liu YH, Wang L, Wei LC, Huang YG, Chen lW. Up-regulation of d-serine might induce gabaergic neuronal degeneration in the cerebral cortex and hippocampus in the mouse pilocarpine model of epilepsy. Neurochem res. 2009;34:1209-18.
127. rossetti AO, Logroscino G, Liaudet L, et al. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. 2007;69:255-60.
128. ryu HJ, Kim JE, Yeo SI, et al. Potential roles of d-serine and serine racemase in experimental temporal lobe epilepsy. J neurosci res. 2010;88:2469-82.
129. robinson JL, Monkul ES, Tordesillas-guti?rez D, et al. Frontolimbic circuitry in euthymic bipolar disorder: evidence for prefrontal hyperactivation. Psychiatry res. 2008;164:106-13.
130. american psychatric association. Diagnostic and Statistical Manual of Mental disorders: dSM-iv. 4th ed. Washington, DC. American psychiatric association 1994:866 P.
131. Chen YS, Akula N, Detera-Wadleigh SD, et al. Findings in an independent sample support an association between bipolar affective disorder and the g72/g30 locus on chromosome 13q33. Mol psychiatry. 2004;9:87-92.
132. hattori E, Liu C, Badner JA, et al. Polymorphisms at the g72/g30 gene locus, On 13q33, Are associated with bipolar disorder in two independent pedigree series. Am J hum genet. 2003;72: 1131-40.
133. Muller DJ, Zai CC, Shinkai T, Strauss J, Kennedy Jl. Association between the daoa/g72 gene and bipolar disorder and metaanalyses in bipolar disorder and schizophrenia. Bipolar disord. 2011;13:198-207.
134. prata D, Breen G, Osborne S, Munro J, St Clair D, Collier D. Association of dao and g72(daoa)/g30 genes with bipolar affective disorder. Am J Med genet b neuropsychiatr genet. 2008;147b:914-7.
135. Schumacher J, Jamra RA, Freudenberg J, et al. Examination of g72 and d-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol psychiatry. 2004;9:203-7.
136. Williams NM, Green EK, Macgregor S, et al. Variation at the daoa/g30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder. Arch gen psychiatry. 2006;63:366-73.
137. Zhang Z, Li Y, Zhao Q, et al. First evidence of association between g72 and bipolar disorder in the Chinese han population. Psychiatr genet. 2009;19:151-3.
138. abou JR, Gobina CM, Becker T, et al. Association study between genetic variants at the vaMp2 and vaMp3 loci and bipolar affective disorder. Psychiatr genet. 2008;18:199-203.
139. hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol psychiatry. 2007; 62:1310-6.
140. robertson CM, Finer NN, Grace Mg. School performance of survivors of neonatal encephalopathy associated with birth asphyxia at term. J pediatr. 1989;114:753-60.
141. Shankaran S, Woldt E, Koepke T, Bedard MP, Nandyal R. Acute neonatal morbidity and long-term central nervous system sequelae of perinatal asphyxia in term infants. Early hum dev. 1991;25:135-48.
142. Sattler R, Tymianski M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol neurobiol. 2001;24:107-29.
143. Mustafa AK, Ahmad AS, Zeynalov E, et al. Serine racemase deletion protects against cerebral ischemia and excitotoxicity. J neurosci. 2010;30:1413-6.
144. goff DC, Coyle Jt. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J psychiatr. 2001;158:1367-77.
145. Murray CJL, Lopez AD, Harvard School of public health; World health organization, World bank. The global burden of disease: a Comprehensive assessment of Mortality and disability from diseases, Injuries, and risk factors in 1990 and projected to 2020. Published by the harvard School of public health on behalf of the World health organization and the World bank; distributed by harvard university press, Cambridge, Ma 1996;vol xxxii.
146. lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for understanding neurotransmitter and riskgene interactions in schizophrenia. Trends neurosci. 2008;31:234-42.
147. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. Psychopharmacology. 1979;65:73-7.
148. Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc natl acad Sci u S A. 1975;72:4376-80.
149. Creese I, Burt DR, Snyder Sh. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481-3.
150. tsai G, Yang P, Chung LC, Lange N, Coyle Jt. D-Serine added to antipsychotics for the treatment of schizophrenia. Biol psychiatry. 1998;44:1081-9.
151. lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch neurol. 2006;63:1372-6.
152. Javitt DC, Zukin Sr. Recent advances in the phencyclidine model of schizophrenia. Am J psychiatry. 1991;148:1301-8.
153. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive nMda antagonist, Ketamine, In humans. Psychotomimetic, Perceptual, Cognitive, and neuroendocrine responses. Arch gen psychiatry. 1994;51:199-214.
154. yee BK, Chang DT, Feldon J. The effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57bl6 mice. Neuropsychopharmacology. 2004;29:1865-77.
155. lipina T, Labrie V, Weiner I, Roder J. Modulators of the glycine site onnMda receptors, D-serine and alX 5407, Display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (berl). 2005;179:54-67.
156. Mandillo S, Rinaldi A, Oliverio A, Mele A. Repeated administration of phencyclidine, Amphetamine and MK-801 selectively impairs spatial learning in mice: a possible model of psychotomimetic drug-induced cognitive deficits. Behav pharmacol. 2003;14:533-44.
157. linn GS, Negi SS, Gerum SV, Javitt dC. Reversal of phencyclidineinduced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology. 2003;169:243-9.
158. Mao CV, Hori E, Maior RS, Ono T, Nishijo H. A primate model of schizophrenia using chronic pCp treatment. Rev neurosci. 2008; 19:83-9.
159. thompson DM, Winsauer PJ, Mastropaolo J. Effects of phencyclidine, Ketamine and MdMa on complex operant behavior in monkeys. Pharmacol biochem behav. 1987;26: 401-5.
160. bubenovvalesovv, Horek J, Vrajov M, H?chl C. Models of schizophrenia in humans and animals based on inhibition of nMda receptors. Neurosci biobehav rev. 2008;32:1014-23.
161. bendikov I, Nadri C, Amar S, et al. A CSf and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr res. 2007;90:41-51.
162. hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog neuropsychopharmacol biol psychiatry. 2005;29:767-9.
163. hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the n-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch gen psychiatry. 2003;60: 572-6.
164. Calcia MA, Madeira C, Alheira FV, et al. Plasma levels of d-serine in brazilian individuals with schizophrenia. Schizophr res. 2012;142:83-7.
165. Kumashiro S, Hashimoto A, Nishikawa T. Free d-serine in postmortem brains and spinal cords of individuals with and without neuropsychiatric diseases. Brain res. 1995;681:117-25.
166. Madeira C, Freitas ME, Vargas-lopes C, Wolosker H, Panizzutti R. Increased brain d-amino acid oxidase (daao) activity in schizophrenia. Schizophr res. 2008;101:76-83.
167. habl G, Zink M, Petroianu G, et al. Increased d-amino acid oxidase expression in the bilateral hippocampal Ca4 of schizophrenic patients: a post-mortem study. J neural transm. 2009;116: 1657-65.
168. allen NC, Bagade S, McQueen MB, et al. Systematic metaanalyses and field synopsis of genetic association studies in schizophrenia: the Szgene database. Nat genet. 2008;40: 827-34.
169. Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr res. 2008;10: 96-107.
170. Sun J, Kuo PH, Riley BP, Kendler KS, Zhao Z. Candidate genes for schizophrenia: a survey of association studies and gene ranking. Am J Med genet b neuropsychiatr genet. 2008;147B:1173-81.
171. burnet PW, Eastwood SL, Bristow GC, et al. D-amino acid oxidase activity and expression are increased in schizophrenia. Mol psychiatry. 2008;13:658-60.
172. Kapoor R, Lim KS, Cheng A, Garrick T, Kapoor V. Preliminary evidence for a link between schizophrenia and nMda-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase (daao) and kynurenine amino transferase-1 (Kat-1). Brain res. 2006;1106:205-10.
173. verrall L, Walker M, Rawlings N, et al. D-amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J neurosci. 2007;26:1657-69.
174. Morita Y, Ujike H, Tanaka Y, et al. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol psychiatry. 2007;61:1200-3.
175. Labrie V, Fukumura R, Rastogi A, et al. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol genet. 2009;18:3227-43.
176. boks MP, Rietkerk T, Van de beek MH, Sommer IE, De Koning TJ, Kahn rS. Reviewing the role of the genes g72 and daao in glutamate neurotransmission in schizophrenia. Eur neuropsychopharmacol. 2007;17:567-72.
177. Caldinelli L, Sacchi S, Molla G, Nardini M, Pollegioni L. Characterization of human daao variants potentially related to an increased risk of schizophrenia. Biochim biophys acta. 2013;1832:400-10.
178. Chumakov I, Blumenfeld M, Guerassimenko O, et al. Genetic and physiological data implicating the new human gene g72 and the gene for d-amino acid oxidase in schizophrenia. Proc natl acad Sci u S A. 2002;99:13675-80.
179. detera-Wadleigh SD, McMahon fJ. G72/g30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol psychiatry. 2006;60:106-14.
180. goldberg TE, Straub RE, Callicott JH, et al. The g72/g30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacol. 2006;31:2022-32.
181. Korostishevsky M, Kaganovich M, Cholostoy A, et al. Is the g72/g30 locus associated with schizophrenia? Single nucleotide polymorphisms, Haplotypes, and gene expression analysis. Biol psychiatry. 2004;56:169-76.
182. Korostishevsky M, Kremer I, Kaganovich M, et al. Transmission disequilibrium and haplotype analyses of the g72/g30 locus: suggestive linkage to schizophrenia in palestinian arabs living in the north of israel. Am J Med genet b neuropsychiatr genet. 2006;141B:91-5.
183. Wang X, He G, Gu N, et al. Association of g72/g30 with schizophrenia in the Chinese population. Biochem biophys res Commun. 2004;319:1281-6.
184. Zou F, Li C, Duan S, et al. A family-based study of the association between the g72/g30 genes and schizophrenia in the Chinese population. Schizophr res. 2005;73:257-61.
185. otte DM, Bilkei-gorza, Filiou Md,et al. Behavioral changes in g72/g30 transgenic mice. Eur neuropsychopharmacol. 2009;5: 339-48.
186. heresco-levy U, Javitt DC, Ebstein R, et al. D-Serine efficacy as add-on pharmacotherapy to risperi-done and olanzapine for treatment-refractory schizophrenia. Biol psychiatry. 2005;57: 577-85.
187. Kantrowitz JT, Malhotra AK, Cornblatt B, et al. High dose d-serine in the treatment of schizophrenia. Schizophr res. 2010;121: 125-30.
188. d'Souza DC, Radhakrishnan R, Perry E, et al. Feasibility, Safety, and efficacy of the combination of d-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study. Neuropsychopharmacol. 2013;38: 492-503.
189. belmaker RH, Agam G. Major depressive disorder. New engl J Med. 2008;358:55-68.
190. van praag H. Monoamine precursors in depression: present state and prospects. In: Zohar J, Belmaker RH, Editors. Treating resistant depression. New york: pMa publishing1987:279-306.
191. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and gabaergic signal transmission with glial involvement in depression. Proc natl acad Sci uSa. 2005;102: 15653-8.
192. lewy AJ, Lefler BJ, Emens JS, Bauer vK. The circadian basis of winter depression. Proc natl acad Sci uSa. 2006;103:7414-9.
193. duman rS. Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues Clin neurosci. 2009;11:239-55.
194. Malkesman O, Austin DR, Tragon T, et al. Acute d-serine treatment produces antidepressant-like effects in rodents. Int J neuropsychopharmacol. 2012;8:1135-48.
195. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, Meador-Woodruff Jh. Decreased nr1, Nr2a, and Sap102 transcript expression in the hippocampus in bipolar disorder. Brain res. 2007;1127:108-18.
196. nudmamud-thanoi S, Reynolds gp. The nr1 subunit of the glutamate/nMda receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci lett. 2004;372: 173-7.
197. banasr M, Chowdhury GM, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, Metabolic and behavioral deficits by the glutamatemodulating drug riluzole. Mol psychiatry. 2010;15:501-11.
198. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch gen psychiatry. 2001;58: 545-53.
199. eby GA, Eby Kl. Rapid recovery from major depression using magnesium treatment. Med hypotheses. 2006;67:362-70.
200. Kroczka B, Bra?ki P, Palucha A, Pilc A, Nowak G. Antidepressantlike properties of zinc in rodent forced swim test. Brain res bull. 2001;55:297-300.
201. Kroczka B, Zi?a A, Dudek D, Pilc A, Nowak G. Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol J pharmacol. 2000;52:403-6.
202. poleszak E, Szewczyk B, Wla? A, et al. D-Serine, A selective glycine/n-methyl-d-aspartate receptor agonist, Antagonizes the antidepressant-like effects of magnesium and zinc in mice. Pharmacol rep. 2008;60:996-1000.
203. gelfin E, Kaufman Y, Korn-lubetzki I, et al. D-Serine adjuvant treatment alleviates behavioural and motor symptoms in parkinson's disease. Int J neuropsychopharmacol. 2012;4: 543-9.
204. braak H, Braak E. Pathoanatomy of parkinson's disease. J neurol Sci. 2000;247:3-10.
205. hoehn MM, Yahr Md. Parkinsonism: onset, Progression and mortality. Neurology. 1967;17:427-42.
206. Starr MS. Antagonists of glutamate in the treatment of parkinson's disease: from laboratory to the clinic. Amino acids. 1998;14: 41-2.
207. hallett PJ, Standaert dg. Rationale for and use of nMda antagonists in parkinson's disease. Pharmacolo ther. 2004;10: 155-74.
208. Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for parkinson's disease. CnS neurol disord drug targets. 2009 dec;8(6):475-91.
209. Crosby NJ, Deane KH, Clarke Ce. Amantadine for dyskinesia in parkinson's disease. Cochrane database Syst rev. 2003;2: 3467-81.
210. del dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov disord. 2001;3: 515-20.
211. verhagen Metman L, Blanchet PJ, Van den Munckhof P, Del dotto P, Natt?r, Chase tn. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov disord. 1998;3:414-7.
212. verhagen Metman L, Del dotto P, Van den Munckhof P, Fang J, Mouradian MM, Chase tn. Amantadine as treatment for dyskinesias and motor fluctuations in parkinson's disease. Neurology. 1998;5:1323-6.
213. blanchet PJ, Metman LV, Mouradian MM, Chase tn. Acute pharmacologic blockade of dyskinesias in parkinson's disease. Mov disord. 1996;5:580-1.